Ganoderic acid A slows osteoarthritis progression by attenuating endoplasmic reticulum stress and blocking NF‐Κb pathway
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.14382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Yuan Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. Hauptthemen laut MEDLINE: NF-kappa B, Osteoarthritis, Heptanoic Acids. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Administration of Jiangxi Province Traditional Chinese Medicine, Double Thousand Plan Foundation of Jiangxi Province Human Resources and Social Security Department, Key Intervertebral Disc Laboratory of Jiangxi Province.
Abstract (Originalsprache)
Osteoarthritis (OA) is a prevalent degenerative pathology, however, there exists a lack of cost‐effective pharmacological interventions that efficaciously inhibit its progression. ganoderic acid A (GAA), a triterpenoid derived from Ganoderma lucidum, possesses antiapoptotic and ‐inflammatory effects. Our objective was to better understand the therapeutic effects of GAA on OA as well as to elucidate the underlying mechanisms of its action. To establish an OA cell model in vitro, chondrocytes (CHONs) were treated with interleukin (IL)‐1β. Subsequently, the investigation was conducted afterward according to the following indicators: cell viability, apoptosis, inflammation, and extracellular matrix (ECM) degradation. Western blotting analysis (WB) was employed to assess both endoplasmic reticulum (ER) stress and proteins associated with the nuclear factor‐kappa B (NF‐κB) signaling pathway. Furthermore, based on molecular docking studies, GAA exhibits a significant binding competence to p65. OA mouse models were constructed by performing a destabilization medial meniscus (DMM) operation. Moreover, histopathology and immunohistochemistry were used to determine the GAA therapeutic effect in reducing OA in vivo. Our findings revealed that GAA has antiapoptotic, anti‐inflammatory, and anti‐ECM degradation effects by inhibiting the ER stress and NF‐κB axis in CHONs in vitro. Furthermore, our findings suggest that GAA may attenuate the progression of osteoarthritis in vivo. GAA can protect CHONs by regulating apoptosis, ECM changes, and inflammation thereby preventing OA progression. These promising results indicate that GAA may be a therapeutic agent for OA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
- Institute of Orthopedics of Jiangxi Province, Nanchang, Jiangxi, China.
- Institute of Minimally Invasive Orthopedics, Nanchang University, Jiangxi, China.
- Jiangxi Key Laboratory of Intervertebral Disc Disease, Nanchang University, Jiangxi, China.
Förderung
- Administration of Jiangxi Province Traditional Chinese Medicine
- Double Thousand Plan Foundation of Jiangxi Province Human Resources and Social Security Department
- Key Intervertebral Disc Laboratory of Jiangxi Province
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Zhou, C., Tan, J., Wu, T., Pan, C., Liu, J., & Cheng, X. (2024). Ganoderic acid A slows osteoarthritis progression by attenuating endoplasmic reticulum stress and blocking NF‐Κb pathway. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14382
Vancouver
Liu Y, Zhou C, Tan J, Wu T, Pan C, Liu J, et al. Ganoderic acid A slows osteoarthritis progression by attenuating endoplasmic reticulum stress and blocking NF‐Κb pathway. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14382
BibTeX
@article{Liu2024,
author = {Liu, Yuan and Zhou, Chuankun and Tan, Jianye and Wu, Tianlong and Pan, Chongzhi and Liu, Jiahao and Cheng, Xigao},
title = {Ganoderic acid A slows osteoarthritis progression by attenuating endoplasmic reticulum stress and blocking NF‐Κb pathway},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.14382}
}
EUVIMED